Schott Pharma with a clear SDAX role, shares tracked against sector peers

Schott Pharma starts the week in the SDAX as investors watch pharma and healthcare peers on Xetra and Frankfurt. Sector moves and the company’s vial business frame the picture for the shares.

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-28, 13:36.

Schott Pharma (DE000A3ENQ51) is part of the German SDAX and listed in Frankfurt, giving the stock a defined role in the small-cap healthcare segment alongside peers such as Bayer and Sartorius. Sector performance in recent sessions offers a reference frame for the shares, according to market data from Frankfurt.

Schott Pharma in the SDAX landscape

Schott Pharma belongs to the SDAX Performance Index on Deutsche Börse, which groups smaller German companies across sectors, including healthcare and pharma names. The inclusion connects the stock to broader movements in Frankfurt trading, where indices such as the SDAX reflect sentiment toward mid and small caps.

Recent SDAX trading has shown mixed performance in Frankfurt, with some sessions ending in losses and others in modest gains, indicating a cautious tone for small caps compared with larger market benchmarks. For Schott Pharma, this index membership frames the equity’s relative position against German peers in healthcare and specialty pharma.

Sector moves and peer comparison

Within the pharma and healthcare sector, larger German names such as Bayer have recently posted marked moves on Xetra, offering a contrast to smaller SDAX constituents. Bayer’s shares climbed more than 20 percent over a seven-day period after a US Supreme Court ruling on glyphosate litigation risk, highlighting how regulatory decisions can drive sector sentiment.

While Schott Pharma operates in a different niche, sector developments in larger names help to shape investor expectations for regulatory exposure, growth prospects and valuation multiples across German-listed healthcare stocks. For retail investors, comparing SDAX constituents such as Schott Pharma with larger peers like Bayer and international players adds context to the stock’s profile.

The product behind the stock

Schott Pharma focuses on high-quality pharmaceutical packaging, including glass vials used for injectable medications and vaccines, and prefillable syringes designed to meet stringent regulatory and patient safety standards. These products support drug makers’ requirements for reliable containment, sterility and compatibility with complex biopharmaceutical formulations.

The listing and current trading

Schott Pharma shares (DE000A3ENQ51) trade in Frankfurt with the ticker 1SXP, quoted in euros and included in the SDAX Performance Index. The latest price information and market capitalization are available via Deutsche Börse and Frankfurt exchange data services, with intraday updates reflecting ongoing investor activity in the small-cap healthcare segment.

Key data on the Schott Pharma shares

• Company: SCHOTT Pharma AG & Co. KGaA
• ISIN: DE000A3ENQ51
• WKN: A3ENQ5
• Ticker: 1SXP
• Trading venue: Frankfurt
• Price (as of 2026-06-28, 13:30): [latest quote] EUR
• Market cap: [latest market cap] EUR (as of 2026-06-28)
• Sector / industry: Pharmaceuticals, packaging for injectable drugs
• Index membership: SDAX Performance Index
• Next earnings date: not officially scheduled

This article provides factual information on Schott Pharma and related sector developments and does not contain investment advice, personal recommendations or any guarantee of future performance.